270 related articles for article (PubMed ID: 25542400)
21. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
22. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
[TBL] [Abstract][Full Text] [Related]
23. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
[TBL] [Abstract][Full Text] [Related]
24. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
25. Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy.
Matsui H; Suzuka K; Yamazawa K; Tanaka N; Mitsuhashi A; Seki K; Sekiya S
Gynecol Oncol; 2005 Mar; 96(3):616-20. PubMed ID: 15721402
[TBL] [Abstract][Full Text] [Related]
26. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
27. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.
Cavoretto P; Gentile C; Mangili G; Garavaglia E; Valsecchi L; Spagnolo D; Montoli S; Candiani M
Ultrasound Obstet Gynecol; 2012 Jul; 40(1):99-105. PubMed ID: 22262502
[TBL] [Abstract][Full Text] [Related]
28. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
29. Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5-6.
Sita-Lumsden A; Medani H; Fisher R; Harvey R; Short D; Sebire N; Savage P; Lim A; Seckl MJ; Agarwal R
BJOG; 2013 Jul; 120(8):1012-5. PubMed ID: 23759086
[TBL] [Abstract][Full Text] [Related]
30. Development of single-agent chemotherapy regimens for gestational trophoblastic disease.
Homesley HD
J Reprod Med; 1994 Mar; 39(3):185-92. PubMed ID: 7518517
[TBL] [Abstract][Full Text] [Related]
31. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
You B; Pollet-Villard M; Fronton L; Labrousse C; Schott AM; Hajri T; Girard P; Freyer G; Tod M; Tranchand B; Colomban O; Ribba B; Raudrant D; Massardier J; Chabaud S; Golfier F
Ann Oncol; 2010 Aug; 21(8):1643-1650. PubMed ID: 20154304
[TBL] [Abstract][Full Text] [Related]
32. The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia.
Banach P; Zaborowski MP; Izycka N; Romala A; Nowak-Markwitz E
Ginekol Pol; 2019; 90(3):141-147. PubMed ID: 30950003
[TBL] [Abstract][Full Text] [Related]
33. Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
You B; Bolze PA; Lotz JP; Massardier J; Gladieff L; Joly F; Hajri T; Maucort-Boulch D; Bin S; Rousset P; Devouassoux-Shisheboran M; Roux A; Alves-Ferreira M; Grazziotin-Soares D; Langlois-Jacques C; Mercier C; Villeneuve L; Freyer G; Golfier F
J Clin Oncol; 2020 Sep; 38(27):3129-3137. PubMed ID: 32716740
[TBL] [Abstract][Full Text] [Related]
34. Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia.
Korkmaz V; Sunar V; Akar S; Alinca CM; Arik Z; Boran N; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Jun; 18(3):326-332. PubMed ID: 34185962
[TBL] [Abstract][Full Text] [Related]
35. Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
Parker VL; Cushen BF; Hills A; Kandiah K; Palmer JE; Singh K; Hancock BW; Tidy JA; Winter MC
Gynecol Oncol; 2023 Feb; 169():34-40. PubMed ID: 36495594
[TBL] [Abstract][Full Text] [Related]
36. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
38. [Trophoblastic diseases].
ten Kate-Booij MJ; Lok CA; Verheijen RH; Massuger LF; van Trommel NE
Ned Tijdschr Geneeskd; 2008 Oct; 152(41):2219-24. PubMed ID: 19009808
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
40. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
